Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68


Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Hartmann L, Haferlach C, Meggendorfer M, Nadarajah N, Kern W, Haferlach T, Stengel A.

Haematologica. 2019 Aug 1. pii: haematol.2019.227702. doi: 10.3324/haematol.2019.227702. [Epub ahead of print]


"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?

Baer C, Walter W, Hutter S, Twardziok S, Meggendorfer M, Kern W, Haferlach T, Haferlach C.

Haematologica. 2019 Aug;104(8):1515-1520. doi: 10.3324/haematol.2019.218917. Epub 2019 Jul 4. No abstract available.


DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern.

Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, Haferlach T, Haferlach C, Höllein A.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0502-0. [Epub ahead of print] No abstract available.


Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R.

Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub 2019 May 7.


RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leuk Lymphoma. 2019 May;60(5):1334-1336. doi: 10.1080/10428194.2018.1522439. No abstract available.


Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Hartmann L, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A.

Genes Chromosomes Cancer. 2019 Oct;58(10):698-704. doi: 10.1002/gcc.22761. Epub 2019 May 1.


Impact of 9q deletions on the classification of patients with acute myeloid leukemia.

Balk B, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

J Cancer Res Clin Oncol. 2019 Mar 29. doi: 10.1007/s00432-019-02908-0. [Epub ahead of print] No abstract available.


Genomic subtyping and therapeutic targeting of acute erythroleukemia.

Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG.

Nat Genet. 2019 Apr;51(4):694-704. doi: 10.1038/s41588-019-0375-1. Epub 2019 Mar 29.


More than a fusion gene: the RUNX1-RUNX1T1 AML.

Haferlach T, Meggendorfer M.

Blood. 2019 Mar 7;133(10):1006-1007. doi: 10.1182/blood-2019-01-896076. No abstract available.


Comprehensive molecular characterization of myeloid malignancies with 9q deletion.

Hartmann L, Haferlach T, Meggendorfer M, Kern W, Haferlach C, Stengel A.

Leuk Lymphoma. 2019 Mar 7:1-3. doi: 10.1080/10428194.2019.1585840. [Epub ahead of print] No abstract available.


Evidence of clonality in cases of hypereosinophilia of undetermined significance.

Pohlkamp C, Vetro C, Dicker F, Meggendorfer M, Kern W, Haferlach C, Haferlach T.

Leuk Lymphoma. 2019 Aug;60(8):2071-2074. doi: 10.1080/10428194.2018.1564825. Epub 2019 Jan 18. No abstract available.


KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.

Jawhar M, Döhner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, Span LLF, Fuhrmann S, Naumann N, Horny HP, Sotlar K, Kubuschok B, von Bubnoff N, Spiekermann K, Heuser M, Metzgeroth G, Fabarius A, Klein S, Hofmann WK, Kluin-Nelemans HC, Haferlach T, Döhner H, Cross NCP, Sperr WR, Valent P, Reiter A.

Leukemia. 2019 May;33(5):1124-1134. doi: 10.1038/s41375-018-0346-z. Epub 2019 Jan 11.


IDH1-R132 changes vary according to NPM1 and other mutations status in AML.

Falini B, Spinelli O, Meggendorfer M, Martelli MP, Bigerna B, Ascani S, Stein H, Rambaldi A, Haferlach T.

Leukemia. 2019 Apr;33(4):1043-1047. doi: 10.1038/s41375-018-0299-2. Epub 2019 Jan 8. No abstract available.


Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Br J Haematol. 2019 Jun;185(5):951-954. doi: 10.1111/bjh.15653. Epub 2018 Nov 20. No abstract available.


NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.


Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease.

Stengel A, Jeromin S, Haferlach T, Meggendorfer M, Kern W, Haferlach C.

Haematologica. 2019 May;104(5):e187-e190. doi: 10.3324/haematol.2018.202952. Epub 2018 Nov 8. No abstract available.


ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion.

Madan V, Han L, Hattori N, Teoh WW, Mayakonda A, Sun QY, Ding LW, Nordin HBM, Lim SL, Shyamsunder P, Dakle P, Sundaresan J, Doan NB, Sanada M, Sato-Otsubo A, Meggendorfer M, Yang H, Said JW, Ogawa S, Haferlach T, Liang DC, Shih LY, Nakamaki T, Wang QT, Koeffler HP.

Haematologica. 2018 Dec;103(12):1980-1990. doi: 10.3324/haematol.2018.189928. Epub 2018 Aug 9.


Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.

Vetro C, Haferlach T, Jeromin S, Stengel A, Zenger M, Nadarajah N, Baer C, Weissmann S, Kern W, Meggendorfer M, Haferlach C.

Br J Haematol. 2018 Oct;183(1):47-59. doi: 10.1111/bjh.15498. Epub 2018 Jul 18.


Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Götze KS.

Oncotarget. 2018 Jun 12;9(45):27882-27894. doi: 10.18632/oncotarget.25328. eCollection 2018 Jun 12. Review.


Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.


The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.

Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T.

Haematologica. 2018 May;103(5):e192-e195. doi: 10.3324/haematol.2017.183160. No abstract available.


Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.

Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C.

Blood. 2018 Jul 12;132(2):187-196. doi: 10.1182/blood-2018-03-837781. Epub 2018 Apr 24.


Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

Höllein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6. No abstract available.


IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.

Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, Haferlach T.

Leukemia. 2018 May;32(5):1249-1253. doi: 10.1038/s41375-018-0026-z. Epub 2018 Jan 30. No abstract available.


Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing.

Stengel A, Nadarajah N, Haferlach T, Dicker F, Kern W, Meggendorfer M, Haferlach C.

Leukemia. 2018 May;32(5):1229-1238. doi: 10.1038/s41375-017-0002-z. Epub 2018 Feb 26. No abstract available.


Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19.


Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.

Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerovà K, Haferlach T, Haferlach C.

Leukemia. 2018 Feb;32(2):295-302. doi: 10.1038/leu.2017.239. Epub 2017 Jul 28.


SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.

Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S.

Leukemia. 2018 Jan;32(1):139-148. doi: 10.1038/leu.2017.183. Epub 2017 Jun 16.


Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T.

Leukemia. 2017 Sep;31(9):1936-1943. doi: 10.1038/leu.2017.190. Epub 2017 Jun 19.


MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C.

Leukemia. 2017 Sep;31(9):1995-1997. doi: 10.1038/leu.2017.180. Epub 2017 Jun 8. No abstract available.


Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.

Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, Metzgeroth G, Fabarius A, Valent P, Hofmann WK, Cross NCP, Meggendorfer M, Reiter A.

Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19.


The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.

Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, Haferlach T, Schmitt K, Fabarius A, Valent P, Hofmann WK, Cross NCP, Metzgeroth G, Reiter A.

Haematologica. 2017 Jun;102(6):1035-1043. doi: 10.3324/haematol.2017.163964. Epub 2017 Mar 2.


Dynamics of clonal evolution in myelodysplastic syndromes.

Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP.

Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.


Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations.

Vetro C, Haferlach C, Haferlach T, Zenger M, Nadarajah N, Kern W, Meggendorfer M.

Leukemia. 2016 Nov;30(11):2235-2238. doi: 10.1038/leu.2016.158. Epub 2016 May 25. No abstract available.


Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.

Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, Meggendorfer M.

Br J Haematol. 2016 Nov;175(3):419-426. doi: 10.1111/bjh.14269. Epub 2016 Jul 22.


The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C.

Leukemia. 2017 Mar;31(3):705-711. doi: 10.1038/leu.2016.263. Epub 2016 Sep 29.


Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U.

Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23. No abstract available.


Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).

Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, Garg M, Lim SL, Madan V, Hattori N, Nagata Y, Miyano S, Yeoh AE, Hou HA, Jiang YY, Takao S, Liu LZ, Tan SZ, Lill M, Hayashi M, Kinoshita A, Kantarjian HM, Kornblau SM, Ogawa S, Haferlach T, Yang H, Koeffler HP.

Leukemia. 2017 Jan;31(1):1-10. doi: 10.1038/leu.2016.160. Epub 2016 Jun 8.


Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M.

Blood. 2016 Sep 8;128(10):1408-17. doi: 10.1182/blood-2016-05-714030. Epub 2016 Jul 6.


Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H, Nowak D.

Blood. 2016 Sep 1;128(9):1246-59. doi: 10.1182/blood-2015-11-679167. Epub 2016 Jun 6.


Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards.

Haferlach T, Weber S, Konietschke R, Nadarajah N, Stengel A, Kern W, Haferlach C, Meggendorfer M.

Leukemia. 2016 Oct;30(10):2123-2125. doi: 10.1038/leu.2016.156. Epub 2016 May 25. No abstract available.


The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.

Stengel A, Kern W, Haferlach T, Meggendorfer M, Haferlach C.

Genes Chromosomes Cancer. 2016 Oct;55(10):777-85. doi: 10.1002/gcc.22377. Epub 2016 Jul 4.


The new provisional WHO entity 'RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia.

Haferlach T, Stengel A, Eckstein S, Perglerová K, Alpermann T, Kern W, Haferlach C, Meggendorfer M.

Leukemia. 2016 Oct;30(10):2109-2112. doi: 10.1038/leu.2016.150. Epub 2016 May 23. No abstract available.


Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T.

Haematologica. 2016 Jul;101(7):830-8. doi: 10.3324/haematol.2016.145888. Epub 2016 Apr 21.


The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.

Meggendorfer M, Haferlach C, Zenger M, Macijewski K, Kern W, Haferlach T.

Leukemia. 2016 Jul;30(7):1624-7. doi: 10.1038/leu.2016.21. Epub 2016 Feb 9. No abstract available.


Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, Haferlach T.

Haematologica. 2016 Feb;101(2):e55-8. doi: 10.3324/haematol.2015.133819. Epub 2015 Oct 15. No abstract available.


Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A.

Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.


Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Meggendorfer M, de Albuquerque A, Nadarajah N, Alpermann T, Kern W, Steuer K, Perglerová K, Haferlach C, Schnittger S, Haferlach T.

Haematologica. 2015 Dec;100(12):e487-90. doi: 10.3324/haematol.2015.127985. Epub 2015 Aug 20. No abstract available.


Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerová K, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2016 Apr;30(4):973-6. doi: 10.1038/leu.2015.207. Epub 2015 Jul 29. No abstract available.


Supplemental Content

Loading ...
Support Center